CEUAX
Price
$62.60
Change
-$0.14 (-0.22%)
Updated
Sep 18 closing price
Net Assets
140.03B
DISCX
Price
$21.32
Change
-$0.16 (-0.74%)
Updated
Sep 18 closing price
Net Assets
2.88B
Interact to see
Advertisement

CEUAX vs DISCX

CEUAX vs DISCX Comparison Chart in %
View a ticker or compare two or three
VS
CEUAX vs. DISCX commentary
Sep 21, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CEUAX is a StrongBuy and DISCX is a StrongBuy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
CEUAX has more cash in the bank: 140B vs. DISCX (2.88B). CEUAX pays higher dividends than DISCX: CEUAX (2.52) vs DISCX (0.00). CEUAX was incepted earlier than DISCX: CEUAX (25 years) vs DISCX (20 years). DISCX (1.99) is less costly to investors than CEUAX (0.86). CEUAX is a more actively managed with annual turnover of: 50.00 vs. DISCX (8.62). CEUAX has a lower initial minimum investment than DISCX: CEUAX (250) vs DISCX (1000). CEUAX annual gain was more profitable for investors over the last year : 2.04 vs. DISCX (-7.63). CEUAX return over 5 years is better than : -4.19 vs. DISCX (-19.43).
CEUAXDISCXCEUAX / DISCX
Total Expense Ratio0.861.9943%
Annual Report Gross Expense Ratio0.861.9943%
Fund Existence25 years20 years-
Gain YTD5.4231.187457%
Front Load4%N/A-
Min. Initial Investment250100025%
Min. Initial Investment IRAN/AN/A-
Net Assets140B2.88B4,854%
Annual Yield % from dividends2.520.00-
Returns for 1 year2.04-7.63-27%
Returns for 3 years27.281.781,529%
Returns for 5 years-4.19-19.4322%
Returns for 10 years51.8440.79127%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FACGX185.571.03
+0.56%
Fidelity Advisor Growth Opps C
HIBCX52.180.13
+0.25%
Hartford Capital Appreciation HLS IB
RYVFX11.69-0.06
-0.51%
Royce Small-Cap Value Service
HFCSX34.31-0.19
-0.55%
Hennessy Focus Investor
FBTDX170.40-3.12
-1.80%
Franklin Biotechnology Discovery C